✦ LIBER ✦

High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia

✍ Scribed by Farag, S S; Bolwell, B J; Elder, P J; Kalaycio, M; Lin, T; Pohlman, B; Penza, S; Marcucci, G; Blum, W; Sobecks, R; Avalos, B R; Byrd, J C; Copelan, E

Book ID: 118676681
Publisher: Nature Publishing Group
Year: 2005
Tongue: English
Weight: 191 KB
Volume: 35
Category: Article
ISSN: 0007-1188
DOI: 10.1038/sj.bmt.1704867

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dose-dependent effect of etoposide in co

Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia

✍ Kröger, N; Zabelina, T; Sonnenberg, S; Krüger, W; Renges, H; Stute, N; Finkenste 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 74 KB

A comparative study of outcomes of idaru

A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia

✍ Li, Qiu-bai; Li, Lei; You, Yong; Chen, Zhi-chao; Xia, Ling-hui; Zou, Ping 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 Chinese ⚖ 382 KB

Predictable prognostic factor of CD56 ex

Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation

✍ Deok-Hwan Yang; Je-Jung Lee; Yeung-Chul Mun; Ho-Jin Shin; Yeo-Kyeoung Kim; Sang- 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 264 KB

The Outcome of Sibling and Unrelated Don

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were Initially Refractory to First Induction Chemotherapy

✍ Gordon Cook; Richard E. Clark; Charles Crawley; Stephen Mackinnon; Nigel Russell 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 206 KB

High dose therapy and autologous stem ce

High dose therapy and autologous stem cell transplant does not improve survival compared with continued combination chemotherapy in people at high risk of relapse after initial treatment of advanced Hodgkin’s lymphoma: Abstracted from: Federico M, Bellei M, Brice P et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy. Journal of Clinical Oncology 2003; 21: 2320–2325

📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 83 KB